Why You Should Buy The Dip On Ironwood Pharmaceuticals (IRWD)

Every once in a while, I cover stocks that I believe are good dip-buying opportunities here. In a vast majority of cases, the setup goes something like this: high-quality business beats earnings, aggressive profit taking ensues, and you’ve got a nice discount on your hands.

A note from our sponsors...

The AI That Could Triple Your Money This Year

Early users could have already tripled their money every single year this AI has been live, based on the average winning trade spotted - WITHOUT having to check the news, WITHOUT watching the Fed, and WITHOUT all the stress most traders have to deal with. For now, you can try this AI yourself, completely free of charge - no email, no credit card.

Click to learn more

That’s not the case this time around. Ironwood Pharmaceuticals (NASDAQ: IRWD) missed earnings estimates for Q1 2026. The latest quarterly report snapped a 3-quarter EPS beat streak. Shares are down about 26% since the data came out.

I realize that all of this sounds less than ideal, and sure, things could have gone better. But the context is important. We’ll get to the context in a few minutes.

Here’s why it’s still a Strong Buy… 

First and foremost, the fundamentals on it are really solid, and even that is an understatement. Our in-house quant rating system, Zen Ratings, grades 4,600 stocks each day on the basis of 115 fundamental factors and metrics. Only the top 5% of stocks are given a Zen Rating of A, equivalent to a Strong Buy, and those stocks have historically provided an average annual return of 32.52%.

IRWD has a Zen Rating of A — it currently ranks in the top 4% of the stocks we track for overall fundamentals. Each Zen Rating is a composite of 7 Component Grade ratings; so we have to look at those to see what it is specifically that makes IRWD enticing.

In a nutshell, it’s great on Value and Financials, and solidly above-average on Growth and Momentum. Safety and Artificial Intelligence rating read below-average, and Sentiment is a problem area. We’re not going to go through all of it — but we are going to have to unpack things and go into a little detail here,.

Ironwood Pharmaceuticals is in the top 1% of stocks for Value. It’s trading at a price-to-earnings (P/E) ratio of 5.59x, and a price-to-earnings growth (PEG) ratio of just 0.18x, which indicates it is severely undervalued. Discounted cash flow (DCF) modeling suggests that the stock is undervalued by as much as 69.80%.

Next up, we have Financials. Here, IRWD is in the top 2%. The company’s profit margin currently stands at 28.3%, and they have $112 million in operating cash flow against a market cap of about $580 million.

Remember that PEG ratio we were talking about a minute ago? It tells us that the stock is undervalued relative to growth prospects. So what are those growth prospects like? Pretty stellar. The Growth Component Grade is a category where IRWD shares rank in the top 6%. Earnings are estimated to grow at 2.5 times the speed of the industry average, and revenue is also forecast to beat the industry average.

Lastly, we have the only real red flag on the list, which is the Sentiment rating. Bottom 12% there for IRWD. Ouch. Roughly 12.6% of shares are currently sold short, and the smart money isn’t piling in.

That’s a definite drawback, but it is slightly ameliorated by the fact that the analyst picture is positive. There isn’t a ton of coverage — only 3 Wall Street researchers cover today’s pick, but they’re quite bullish. We’ve got 2 Buy ratings and 1 Hold rating. The lowest price target on the Street implies an upside of almost 40%, the average forecast calls for about 114%, and the most bullish target implies almost 180%.

Those are the fundamentals — but I also promised I’d mention some context that puts everything into perspective as well.

First off, IRWD has rallied by more than 500% in the past 365 days. The 26% pullback we’ve seen is still major — but when stuff like that happens after a monster rally, I’m much more inclined to believe it’s position trimming and profit-taking rather than abandoning ship completely.

Secondly, the earnings miss was not exactly major. The forecast called for $0.25, and Ironwood delivered $0.24. Even though they missed estimates, earnings per share for the quarter grew by 204% on a year-over-year (YoY) basis.

There’s more than enough here to make me feel comfortable. Strong financials, earnings and revenue growth estimates that outclass the industry, and a valuation that’s fair relative to growth prospects. Wall Street’s bullishness is just the cherry on top.

One last note. Unlike most of the stocks I cover, I’m not necessarily 100% on board with buying IRWD straight away. I think buying right now would be perfectly fine — but I can just as easily see more of a pullback in the cards that could provide a better entry point. Provided that it doesn’t see a quick (and meaningful) reversal, I’m going to see how the next week or two play out in terms of price action before pulling the trigger.

—> Click here to research IRWD

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.